Companies in the life sciences must tread carefully when it comes to the Anti-Kickback Statute, but a recent advisory opinion by the Office of Inspector General lends little clarity on the point.
Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND clearance in China Jan. 10 and the U.S. on May 30, Circode CEO Chenxiang Tang recently told BioWorld.
Actithera A/S is poised to bring small-molecule pharmacokinetics to radiopharmaceuticals after closing a $75.5 million series A that will fund initial clinical development of a candidate targeting the elusive fibroblast activation protein (FAP).
Dana Farber Cancer Institute Inc. and Stanford University have patented new molecular glue degraders comprising cereblon (CRBN) binding moiety acting as casein kinase 1 isoform α and/or wee1-like protein kinase (Wee1) degradation inducers reported to be useful for the treatment of cancer.
Researchers from Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have discovered GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Incyte Corp. has described GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Prostate cancer is one of the most common male-related cancers, and understanding the underlying mechanisms is crucial for developing new treatment strategies and avoiding resistance development.
Mitsubishi Tanabe Pharma Corp., Veneno Technologies Co. Ltd. and Alpha Fusion Co. Ltd. have initiated a joint research collaboration in Japan to develop cancer drugs using targeted alpha therapy (TAT).
The med tech patent wars opened a new front in the region of screening tests for colorectal cancer, pitting Exact Sciences Corp., of Madison, Wisc., against St. Louis-based Geneoscopy Inc.
Actithera A/S is poised to bring small-molecule pharmacokinetics to radiopharmaceuticals after closing a $75.5 million series A that will fund initial clinical development of a candidate targeting the elusive fibroblast activation protein (FAP).
RSS
